AXS-12 (reboxetine) for Narcolepsy (cataplexy)
The FDA is expected to decide on AXS-12 for Narcolepsy (cataplexy) by May 1, 2027, under a NDA from Axsome Therapeutics.
What is being decided
Axsome Therapeutics has a NDA under FDA review for AXS-12 (reboxetine) in Narcolepsy (cataplexy). Norepinephrine reuptake inhibitor targeting cataplexy in narcolepsy.
Who this decision matters to
Narcolepsy type 1 is a chronic neurologic disorder caused by loss of hypocretin-producing neurons, resulting in severe daytime somnolence and cataplexy. HLA-DQB1*0602 association and brain imaging support the autoimmune hypothesis. Medications enhance wakefulness; behavioral approaches optimize quality of life.
Prevalence: 1 in 2,000 to 3,000 people; often undiagnosed. See our full Narcolepsy Type 1 page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Narcolepsy Type 1 treatment stands today
Medications enhancing central nervous system wakefulness form the foundation of therapy: stimulants including modafinil (first-line), armodafinil, methylphenidate, and amphetamine derivatives manage excessive daytime sleepiness. Sodium oxybate (GHB) addresses both EDS and cataplexy and improves nighttime sleep; it is the most effective agent for cataplexy but requires careful dosing and patient education. Pitolisant, a histamine H3-receptor antagonist, offers an alternative mechanism for both EDS and cataplexy and is gaining clinical adoption. Selective serotonin or norepinephrine reuptake inhibitors (SSRIs/SNRIs) manage cataplexy alone. Behavioral strategies including scheduled naps (10-20 minutes), strict sleep hygiene, avoidance of sedating medications, and comprehensive safety measures optimize quality of life. Clinical trials investigating immune-based therapies targeting HLA-DQB1*0602 or hypocretin neuron antibodies are underway. Genetic counseling helps families understand disease mechanism and inheritance patterns. Work with sleep medicine specialists experienced in narcolepsy management.
Meanwhile, 24 Narcolepsy Type 1 trials are recruiting
Whatever the FDA decides here, research on Narcolepsy Type 1 does not stop. A few currently enrolling studies, US sites first:
Get notified when new narcolepsy-type-1 trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on AXS-12?
The FDA's target decision date (PDUFA date) for AXS-12 in Narcolepsy (cataplexy) is May 1, 2027, disclosed by Axsome Therapeutics. The agency can act before this date and occasionally runs past it.
What is AXS-12 being reviewed for?
Axsome Therapeutics submitted a NDA for AXS-12 in Narcolepsy (cataplexy). Norepinephrine reuptake inhibitor targeting cataplexy in narcolepsy.
What happens after the AXS-12 decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Axsome press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.